SCHEDULE 13G/A: BlackRock Discloses 4.6% Passive Stake in Compass Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.6% beneficial ownership stake in Compass Therapeutics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 6,398,988 shares of Compass Therapeutics, Inc. Common Stock.
- This ownership represents 4.6% of the total outstanding class of securities.
- BlackRock, Inc. holds sole voting power over 6,262,843 shares and sole dispositive power over 6,398,988 shares.
- No shared voting or dispositive power is reported.
- The filing is an Amendment No. 1 to a previous Schedule 13G.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Compass Therapeutics, Inc.
- Certain BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management, LLC, are identified as entities through which the securities are held, with at least one entity beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing disclosing beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news for the issuer.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment stake in a publicly traded biotechnology company, Compass Therapeutics, Inc. Such filings are common for large investment firms managing diverse portfolios on behalf of clients.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, indicating BlackRock's continued passive investment.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution for the Power of Attorney granted by BlackRock, Inc. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-16 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Compass Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.